 Nabriva Therapeutics PLC ADR NASDAQ:NBRV shares are trading higher by 48 at 2.19 Wednesday morning after the company, and Sinovant Sciences, announced topline results from the Phase 3 trial of lefamulin in Chinese adults with community-acquired bacterial pneumonia. Nabriva Therapeutics is a clinical-stage biopharmaceutical company. 